Alzheon
is a Massachusetts-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of Alzheimer’s disease and neurological disorders... Read moreAlzheon
is a Massachusetts-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of Alzheimer’s disease and neurological disorders... Read more
News
Apr 07, 2026
StreetInsider
Press Release: Alzheon : Alzheon Advances Industry-Leading Portfolio of Oral Anti-Amyloid Aggregation Inhibitors with First Subject Dosed in Phase 1 of ALZ-507, Highlighting Potential for Once-Daily Administration, Improved S
Mar 10, 2026
StreetInsider
Press Release: Alzheon : Alzheon to Present Clinical, Imaging, and Fluid Biomarker Results from Trials with Oral Valiltramiprosate/ALZ-801 at 2026 AD/PD Conference in Copenhagen, Denmark
Dec 02, 2025
StreetInsider
Press Release: Alzheon : Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Alzheimer's Disease
Nov 19, 2025
StreetInsider
Press Release: Alzheon : Alzheon to Present Multiple Clinical, Neuroimaging and Modeling Results for Oral Valiltramiprosate/ALZ-801 from Phase 2 and 3 Studies at CTAD Conference in San Diego, December 1-4, 2025
Jul 15, 2025
StreetInsider
Press Release: Alzheon : Alzheon to Present Insights into Oral Valiltramiprosate/ALZ-801 Mode of Action and Clinical Efficacy at Dedicated Symposium at Alzheimer's Association International Conference in Toronto on July 30t
Apr 11, 2025
Clinical Trials Arena
Alzheon: Alzheon's Alzheimer's pill fails in Phase III trial
Apr 10, 2025
MedCity News
Alzheon: Alzheon's Precision Medicine Approach to Resurrect an Alzheimer's Drug Fails Pivotal Study
Apr 03, 2025
BioCentury
Alzheon: Amid Alzheon Alzheimer's setback, PIs see new surrogate endpoint
Mar 18, 2025
FinanzNachrichten
Alzheon: Alzheon, Inc.: Alzheon to Present Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 at Dedicated Symposium at ADPD Conference in Vienna on April 1st, 2025
Sep 18, 2024
Business Wire
Press Release: Alzheon : New Alzheon Peer-Reviewed Scientific Publication Describes Study Design and Baseline Characteristics from APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate in APOE4/4 Homozygous Individuals with Early Alzheimer's Disease
Alzheon Competitors
1
2
3
4
5
6
7
8
9
10